These latest guidelines – for healthcare professionals only – define the role of diagnostic and treatment modalities in the management of patients with chronic liver disease.
The following recommendations are defined by internationally recognized scientific organizations and are based on the best available research data and practical experience.
The National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued landmark guidance recommending the use of FibroScan®, citing that it may improve the early detection of liver disease in primary and community care settings.
The new Practice Guidance from the AASLD suggests the use of VCTE™, a patented technology used by FibroScan® solutions from Echosens, for detecting and diagnosing NAFLD in high-risk individuals, including those with type 2 diabetes (T2D).
These Baveno VII guidelines applies for the management of patients with advanced chronic liver disease.
These new guidelines are a breakthrough in early diagnosis and management of patients with NAFLD targeting primary care and endocrinology clinical settings.
The purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.